| Product Code: ETC13360064 | Publication Date: Apr 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | No. of Pages: 150 | No. of Figures: 55 | No. of Tables: 32 |
Europe Human Microbiome-Based Drugs and Diagnostics Market |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Europe Human Microbiome-Based Drugs and Diagnostics Market Overview |
3.1 Europe Regional Macro Economic Indicators |
3.2 Europe Human Microbiome-Based Drugs and Diagnostics Market Revenues & Volume, 2021 & 2031F |
3.3 Europe Human Microbiome-Based Drugs and Diagnostics Market - Industry Life Cycle |
3.4 Europe Human Microbiome-Based Drugs and Diagnostics Market - Porter's Five Forces |
3.5 Europe Human Microbiome-Based Drugs and Diagnostics Market Revenues & Volume Share, By Countries, 2021 & 2031F |
3.6 Europe Human Microbiome-Based Drugs and Diagnostics Market Revenues & Volume Share, By Drug Category, 2021 & 2031F |
3.7 Europe Human Microbiome-Based Drugs and Diagnostics Market Revenues & Volume Share, By Diagnostic Category, 2021 & 2031F |
3.8 Europe Human Microbiome-Based Drugs and Diagnostics Market Revenues & Volume Share, By Target Organism, 2021 & 2031F |
3.9 Europe Human Microbiome-Based Drugs and Diagnostics Market Revenues & Volume Share, By Application Area, 2021 & 2031F |
3.10 Europe Human Microbiome-Based Drugs and Diagnostics Market Revenues & Volume Share, By End Use, 2021 & 2031F |
4 Europe Human Microbiome-Based Drugs and Diagnostics Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 Europe Human Microbiome-Based Drugs and Diagnostics Market Trends |
6 Europe Human Microbiome-Based Drugs and Diagnostics Market, 2021 - 2031 |
6.1 Europe Human Microbiome-Based Drugs and Diagnostics Market, Revenues & Volume, By Drug Category, 2021 - 2031 |
6.1.1 Overview & Analysis |
6.1.2 Europe Human Microbiome-Based Drugs and Diagnostics Market, Revenues & Volume, By Probiotics, 2021 - 2031 |
6.1.3 Europe Human Microbiome-Based Drugs and Diagnostics Market, Revenues & Volume, By Prebiotics, 2021 - 2031 |
6.1.4 Europe Human Microbiome-Based Drugs and Diagnostics Market, Revenues & Volume, By Symbiotics, 2021 - 2031 |
6.1.5 Europe Human Microbiome-Based Drugs and Diagnostics Market, Revenues & Volume, By Fecal Transplant, 2020 - 2028 |
6.2 Europe Human Microbiome-Based Drugs and Diagnostics Market, Revenues & Volume, By Diagnostic Category, 2021 - 2031 |
6.2.1 Overview & Analysis |
6.2.2 Europe Human Microbiome-Based Drugs and Diagnostics Market, Revenues & Volume, By Microbial Profiling, 2021 - 2031 |
6.2.3 Europe Human Microbiome-Based Drugs and Diagnostics Market, Revenues & Volume, By Microbial DNA Testing, 2021 - 2031 |
6.2.4 Europe Human Microbiome-Based Drugs and Diagnostics Market, Revenues & Volume, By Polymerase Chain Reaction (PCR), 2021 - 2031 |
6.2.5 Europe Human Microbiome-Based Drugs and Diagnostics Market, Revenues & Volume, By Genomic Profiling, 2021 - 2031 |
6.3 Europe Human Microbiome-Based Drugs and Diagnostics Market, Revenues & Volume, By Target Organism, 2021 - 2031 |
6.3.1 Overview & Analysis |
6.3.2 Europe Human Microbiome-Based Drugs and Diagnostics Market, Revenues & Volume, By Gut Microbiome, 2021 - 2031 |
6.3.3 Europe Human Microbiome-Based Drugs and Diagnostics Market, Revenues & Volume, By Oral Microbiome, 2021 - 2031 |
6.3.4 Europe Human Microbiome-Based Drugs and Diagnostics Market, Revenues & Volume, By Skin Microbiome, 2021 - 2031 |
6.3.5 Europe Human Microbiome-Based Drugs and Diagnostics Market, Revenues & Volume, By Vaginal Microbiome, 2021 - 2031 |
6.4 Europe Human Microbiome-Based Drugs and Diagnostics Market, Revenues & Volume, By Application Area, 2021 - 2031 |
6.4.1 Overview & Analysis |
6.4.2 Europe Human Microbiome-Based Drugs and Diagnostics Market, Revenues & Volume, By Gastrointestinal Health, 2021 - 2031 |
6.4.3 Europe Human Microbiome-Based Drugs and Diagnostics Market, Revenues & Volume, By Oral Health, 2021 - 2031 |
6.4.4 Europe Human Microbiome-Based Drugs and Diagnostics Market, Revenues & Volume, By Dermatological Disorders, 2020 - 2028 |
6.4.5 Europe Human Microbiome-Based Drugs and Diagnostics Market, Revenues & Volume, By Immune Modulation, 2020 - 2028 |
6.5 Europe Human Microbiome-Based Drugs and Diagnostics Market, Revenues & Volume, By End Use, 2020 - 2028 |
6.5.1 Overview & Analysis |
6.5.2 Europe Human Microbiome-Based Drugs and Diagnostics Market, Revenues & Volume, By Digestive Disorders, 2020 - 2028 |
6.5.3 Europe Human Microbiome-Based Drugs and Diagnostics Market, Revenues & Volume, By Periodontal Disease, 2020 - 2028 |
6.5.4 Europe Human Microbiome-Based Drugs and Diagnostics Market, Revenues & Volume, By Skin Health, 2020 - 2028 |
6.5.5 Europe Human Microbiome-Based Drugs and Diagnostics Market, Revenues & Volume, By Vaginal Health, 2020 - 2028 |
7 Europe Human Microbiome-Based Drugs and Diagnostics Market, By Countries, 2021 - 2031 |
7.1 Overview & Analysis |
7.2 Europe Human Microbiome-Based Drugs and Diagnostics Market, Revenues & Volume, By Drug Category, 2021 - 2031 |
7.2.1 United Kingdom (UK) Human Microbiome-Based Drugs and Diagnostics Market, Revenues & Volume, By Drug Category, 2021 - 2031 |
7.2.2 Germany Human Microbiome-Based Drugs and Diagnostics Market, Revenues & Volume, By Drug Category, 2021 - 2031 |
7.2.3 France Human Microbiome-Based Drugs and Diagnostics Market, Revenues & Volume, By Drug Category, 2021 - 2031 |
7.2.4 Poland Human Microbiome-Based Drugs and Diagnostics Market, Revenues & Volume, By Drug Category, 2021 - 2031 |
7.2.5 Spain Human Microbiome-Based Drugs and Diagnostics Market, Revenues & Volume, By Drug Category, 2021 - 2031 |
7.2.6 Rest of Europe Human Microbiome-Based Drugs and Diagnostics Market, Revenues & Volume, By Drug Category, 2021 - 2031 |
7.3 Europe Human Microbiome-Based Drugs and Diagnostics Market Revenues & Volume Share, By Diagnostic Category, 2021 & 2031F |
7.3.1 United Kingdom (UK) Human Microbiome-Based Drugs and Diagnostics Market, Revenues & Volume, By Diagnostic Category, 2021 - 2031 |
7.3.2 Germany Human Microbiome-Based Drugs and Diagnostics Market, Revenues & Volume, By Diagnostic Category, 2021 - 2031 |
7.3.3 France Human Microbiome-Based Drugs and Diagnostics Market, Revenues & Volume, By Diagnostic Category, 2021 - 2031 |
7.3.4 Poland Human Microbiome-Based Drugs and Diagnostics Market, Revenues & Volume, By Diagnostic Category, 2021 - 2031 |
7.3.5 Spain Human Microbiome-Based Drugs and Diagnostics Market, Revenues & Volume, By Diagnostic Category, 2021 - 2031 |
7.3.6 Rest of Europe Human Microbiome-Based Drugs and Diagnostics Market, Revenues & Volume, By Diagnostic Category, 2021 - 2031 |
7.4 Europe Human Microbiome-Based Drugs and Diagnostics Market, Revenues & Volume, By Target Organism, 2021 - 2031 |
7.4.1 United Kingdom (UK) Human Microbiome-Based Drugs and Diagnostics Market, Revenues & Volume, By Target Organism, 2021 - 2031 |
7.4.2 Germany Human Microbiome-Based Drugs and Diagnostics Market, Revenues & Volume, By Target Organism, 2021 - 2031 |
7.4.3 France Human Microbiome-Based Drugs and Diagnostics Market, Revenues & Volume, By Target Organism, 2021 - 2031 |
7.4.4 Poland Human Microbiome-Based Drugs and Diagnostics Market, Revenues & Volume, By Target Organism, 2021 - 2031 |
7.4.5 Spain Human Microbiome-Based Drugs and Diagnostics Market, Revenues & Volume, By Target Organism, 2021 - 2031 |
7.4.6 Rest of Europe Human Microbiome-Based Drugs and Diagnostics Market, Revenues & Volume, By Target Organism, 2021 - 2031 |
7.5 Europe Human Microbiome-Based Drugs and Diagnostics Market, Revenues & Volume, By Application Area, 2021 - 2031 |
7.5.1 United Kingdom (UK) Human Microbiome-Based Drugs and Diagnostics Market, Revenues & Volume, By Application Area, 2021 - 2031 |
7.5.2 Germany Human Microbiome-Based Drugs and Diagnostics Market, Revenues & Volume, By Application Area, 2021 - 2031 |
7.5.3 France Human Microbiome-Based Drugs and Diagnostics Market, Revenues & Volume, By Application Area, 2021 - 2031 |
7.5.4 Poland Human Microbiome-Based Drugs and Diagnostics Market, Revenues & Volume, By Application Area, 2021 - 2031 |
7.5.5 Spain Human Microbiome-Based Drugs and Diagnostics Market, Revenues & Volume, By Application Area, 2021 - 2031 |
7.5.6 Rest of Europe Human Microbiome-Based Drugs and Diagnostics Market, Revenues & Volume, By Application Area, 2021 - 2031 |
7.6 Europe Human Microbiome-Based Drugs and Diagnostics Market, Revenues & Volume, By End Use, 2021 - 2031 |
7.6.1 United Kingdom (UK) Human Microbiome-Based Drugs and Diagnostics Market, Revenues & Volume, By End Use, 2021 - 2031 |
7.6.2 Germany Human Microbiome-Based Drugs and Diagnostics Market, Revenues & Volume, By End Use, 2021 - 2031 |
7.6.3 France Human Microbiome-Based Drugs and Diagnostics Market, Revenues & Volume, By End Use, 2021 - 2031 |
7.6.4 Poland Human Microbiome-Based Drugs and Diagnostics Market, Revenues & Volume, By End Use, 2021 - 2031 |
7.6.5 Spain Human Microbiome-Based Drugs and Diagnostics Market, Revenues & Volume, By End Use, 2021 - 2031 |
7.6.6 Rest of Europe Human Microbiome-Based Drugs and Diagnostics Market, Revenues & Volume, By End Use, 2021 - 2031 |
8 Europe Human Microbiome-Based Drugs and Diagnostics Market Key Performance Indicators |
9 Europe Human Microbiome-Based Drugs and Diagnostics Market - Export/Import By Countries Assessment |
10 Europe Human Microbiome-Based Drugs and Diagnostics Market - Opportunity Assessment |
10.1 Europe Human Microbiome-Based Drugs and Diagnostics Market Opportunity Assessment, By Countries, 2021 & 2031F |
10.2 Europe Human Microbiome-Based Drugs and Diagnostics Market Opportunity Assessment, By Drug Category, 2021 & 2031F |
10.3 Europe Human Microbiome-Based Drugs and Diagnostics Market Opportunity Assessment, By Diagnostic Category, 2021 & 2031F |
10.4 Europe Human Microbiome-Based Drugs and Diagnostics Market Opportunity Assessment, By Target Organism, 2021 & 2031F |
10.5 Europe Human Microbiome-Based Drugs and Diagnostics Market Opportunity Assessment, By Application Area, 2021 & 2031F |
10.6 Europe Human Microbiome-Based Drugs and Diagnostics Market Opportunity Assessment, By End Use, 2021 & 2031F |
11 Europe Human Microbiome-Based Drugs and Diagnostics Market - Competitive Landscape |
11.1 Europe Human Microbiome-Based Drugs and Diagnostics Market Revenue Share, By Companies, 2022 |
11.2 Europe Human Microbiome-Based Drugs and Diagnostics Market Competitive Benchmarking, By Operating and Technical Parameters |
12 Top 10 Company Profiles |
13 Recommendations |
14 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here